EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction

Mauro Acquaro, Laura Scelsi, Camilla Mascolo, Costantino Pelosi, Alessandra Greco, Annalisa Turco, Sandra Schirinzi, Mariangela Lattanzio, Tullia Resasco, Valentina Mercurio, Claudio Di Lorenzo, Edoardo Marovino und 2 weitere

Journal of the American Society of Echocardiography · 2025

DOI: 10.1016/j.echo.2024.10.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Society of Echocardiography, 2025. Verfasst von Mauro Acquaro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: mauro.acquaro.md@gmail.com. Hauptthemen laut MEDLINE: Glucosides, Heart Failure, Benzhydryl Compounds, Stroke Volume. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The benefits of sodium glucose cotransporter 2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) have been clearly demonstrated in randomized clinical trials. However, the mechanisms of the observed beneficial effects remain incompletely understood. This study aimed to assess morphofunctional cardiac changes following dapagliflozin introduction in stable outpatients with HFrEF and to investigate whether these changes were determinants of the improved clinical outcome. METHODS: In this multicenter, prospective observational study, 300 consecutive HFrEF patients ≥18 years old on optimized medical therapy and eligible for dapagliflozin therapy were enrolled between April 2022 and January 2023. Laboratory and echocardiographic assessments were performed at baseline and after a median of 6 months. RESULTS: Following dapagliflozin initiation, 47% of patients achieved a target of improvement in left ventricular end-diastolic volume (Δ EDVi 10%) at 6 months. The proportion of patients with elevated left ventricular filling pressures decreased from 26% to 3% at 6 months (P < .001). The combination of left ventricular remodeling and filling pressures improvements was associated with absence of heart failure-related hospitalizations and significant natriuretic peptide reduction at 12 months. CONCLUSIONS: Dapagliflozin determined left ventricular remodeling and improved left ventricular filling pressures in a high proportion of patients with stable HFrEF patients already on optimized medical therapy. These improvements were associated with absence of heart failure-related hospitalizations and a significant natriuretic peptide reduction at 12 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesHeart FailureBenzhydryl CompoundsStroke VolumeVentricular RemodelingSodium-Glucose Transporter 2 InhibitorsHeart VentriclesVentricular PressureHumansMaleFemaleProspective StudiesAgedMiddle AgedEchocardiographyTreatment OutcomeVentricular Function, Left

Stichwörter der Autor:innen

DapagliflozinDiastolic functionHeart failure with reduced ejection fractionRemodelingSGLT2i

Substanzen

dapagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: mauro.acquaro.md@gmail.com.
  • Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Division of Cardiology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
  • Division of Cardiology, Ospedale Maggiore di Lodi, Lodi, Italy.
  • Division of Cardiology, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy.

Zitieren

APA

Acquaro, M., Scelsi, L., Mascolo, C., Pelosi, C., Greco, A., Turco, A., Schirinzi, S., Lattanzio, M., Resasco, T., Mercurio, V., Di Lorenzo, C., Marovino, E., De Luca, L., & Ghio, S. (2025). Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction. Journal of the American Society of Echocardiography. https://doi.org/10.1016/j.echo.2024.10.009

Vancouver

Acquaro M, Scelsi L, Mascolo C, Pelosi C, Greco A, Turco A, et al. Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction. Journal of the American Society of Echocardiography. 2025. doi:10.1016/j.echo.2024.10.009

BibTeX
@article{Acquaro2025,
  author = {Acquaro, Mauro and Scelsi, Laura and Mascolo, Camilla and Pelosi, Costantino and Greco, Alessandra and Turco, Annalisa and Schirinzi, Sandra and Lattanzio, Mariangela and Resasco, Tullia and Mercurio, Valentina and Di Lorenzo, Claudio and Marovino, Edoardo and De Luca, Leonardo and Ghio, Stefano},
  title = {Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction},
  journal = {Journal of the American Society of Echocardiography},
  year = {2025},
  doi = {10.1016/j.echo.2024.10.009}
}
Kostenlos starten →